Clinical Trial Detail

NCT ID NCT03371381
Title An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Janssen Research & Development, LLC
Indications

lung adenocarcinoma

Therapies

JNJ-64041757 + Nivolumab

Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST